About Us

OUR STORY

Founded in 2020, I2Pure's vision for the potential applications of molecular iodine knows few boundaries. We believe that, properly used, molecular iodine has the potential to change the way that global societies think about:

  • Infection prevention in healthcare settings and our daily lives
  • Global water disinfection for cost-effective, cleaner drinking water worldwide
  • Food and produce cleaning and preservation
  • Animal health
  • Industrial cleaning applications, such as surface disinfectants or clean-in-place solutions

A few short years later, I2Pure is a growing healthcare technology company. With a vision to impact global health, I2Pure has dedicated its efforts to advancing the world of health and biosafety by preventing infections and disease through its patented, non-toxic molecular iodine platform.

Directing our scientific endeavors is one of the few chemists in history to have dedicated his career to the study of molecular iodine - Dr. Jack Kessler, PhD. Over a span of 40+ years, Dr. Kessler has been a world leader in understanding molecular iodine and formulating novel ways to deliver high levels of molecular iodine in a pH-neutral manner that is non-toxic and non-staining.

DEDICATED TO THE MISSION

Our mission is clear and simple: Preventing pathogenic threats to the world.

To achieve this mission, I2Pure has developed a iodine technologies that can be used across virtually every facet of surgical and therapeutic interaction with human or animal tissue to prevent infection.

Infinitely flexible, I2Pure molecular iodine solutions can be delivered via liquids, solids, semi-solids, polymers and coatings and can be extended into medical devices, antisepsis, cosmetics, water safety, food safety and preservation, aquaculture and more.

Helping to shape the direction of product offerings is a leadership team with significant global experience in the life sciences, healthcare and defense industries, among others. Individuals passionate about the pursuit of I2Pure's mission and vision are present at all levels of our company.  

OUR WORLDCLASS SCIENTISTS

Our Chief Scientific Officer, Dr. Kessler continues his ground-breaking work on the use of iodine to improve the world. His chemistry focuses molecular iodine’s natural biocidal properties on the cellular destabilization and subsequent eradication of pathogens. His formulations are at the heart of several ground-breaking products already used by the dental and agricultural industries.

Our Chief Scientist, Dr. Ilker Bayer, PhD. has extensive experience researching functional coatings, hybrid nanomaterials, controlled drug release technologies and bio-based polymer composites for applications in biomedical engineering. He was a researcher in the Mechanical and Aerospace Engineering departments at the University of Illinois and University of Virginia, and a longtime research scientist at the Italian Institute of Technology.

Dr. Eugene Duan, PhD. - our Analytical Chemist, brings a particular skill to I2Pure in the ability to measure molecular iodine in formulation and the release of molecular iodine over time. Dr. Duan has likewise spent his career studying molecular iodine and its application to some of the world’s most fundamental challenges, such as the reliable and inexpensive disinfection of water.

LEADERSHIP
Jeff Jochims Jeff Jochims
CEO

Jeff Jochims

Chief Executive Officer

25+ years of leadership in the life sciences and healthcare industries, including long executive tenures at industry leaders Thermo Fisher Scienfic and Owens & Minor. Mr. Jochims has deep experience in entrepreneurial start-ups as well as global life sciences and healthcare companies of all sizes. Businesses under Jochims’ influence have consistently delivered customer-centric operational excellence and market share gains.

C-suite Officer at NYSE:OMI (COO) & 15 years as an executive leader at NYSE:TMO (Global President, Fisher Scientific). Educ: JD (U of Pittsburgh) & BA (U of Illinois).

email Jeff Jochims    
Ilker Bayer Dr. Ilker Bayer
Chief Scientist

Dr. Ilker Bayer

Chief Scientist

Dr. Bayer completed his doctoral studies in chemical engineering at the University of Illinois, where his research concentrated on the interactions between surfaces and liquids, as well as interface science. He was a visiting and post-doctoral researcher in the Mechanical and Aerospace Engineering Departments at both the University of Illinois and the University of Virginia. Subsequently, Dr. Bayer served as a research scientist at the Italian Institute of Technology (iit) for fifteen years. He holds the position of visiting professor at the University of Virginia.

Dr. Bayer's research endeavors primarily revolve around functional coatings, hybrid nanomaterials, controlled drug release, and the development of bio-based polymer composites for applications in biomedical engineering. According to Google Scholar his h-index is 62 and Dr. Bayer has been involved in the filing and granting of thirty patents, demonstrating his innovative approach and commitment to advancing scientific knowledge and technological advancements

Eugene Duan Dr. Eugene Duan
Analytical Chemist

Dr. Eugene Duan

Analytical Chemist

Dr. Duan's focus is on iodine technological research and product developments in the fields of dermatology, medical devices, medicine, and agricultural as well as aquacultural disinfectants. Before joining I2Pure, Dr. Duan served as a consultant for several companies in product research and marketing.

Dr. Duan founded and was a co-partner in three companies in China with a focus in the fields of agriculture and aquaculture, medical devices, and pharmaceuticals. He held various positions including legal representative, chair of board, president, vice president or chief technology officer, with these firms. He was with Symbollon Pharmaceuticals as a senior scientist and later as director of the research and development department from 1994 to 2002. He has authored over a dozen publications and patents and obtained various degrees and awards.

ADVISORS
Jack Kessler Dr. Jack Kessler
Chief Scientific Officer

Dr. Jack Kessler

Chief Scientific Officer

World-renowned scientist on molecular iodine technology. Past senior scientist at Hoffman-LaRoche & senior principal systems engineer at Elbit Systems of America. He was senior scientist in new technology evaluation at Hoffman-LaRoche, before becoming senior principal systems engineer at Elbit Systems of America. Kessler is a member of the founding team of Symbollon Pharmaceuticals, Iotech International, and I2Pure, where he is Chief Science Officer.

Victor Nizet Dr. Victor Nizet
Chief Medical Officer

Dr. Victor Nizet

Chief Medical Officer

Dr. Nizet is a professor of Pediatrics, Vice Chair for Basic Research, and Chief of the Division of Host-Microbe Systems & Therapeutics at the University of California, San Diego (UCSD) School of Medicine. He is also a professor at UCSD Skaggs School of Pharmacy & Pharmaceutical Sciences. He has authored over 520 peer-reviewed publications and has collaborated with biotechnology professionals in developing new antibiotic and immune-based therapies or vaccines.

At UC San Diego, he leads a large basic and translational research laboratory studying bacterial pathogenesis, innate immunity, and novel approaches to the treatment of antibiotic-resistant pathogens and sepsis.

Dr. Peter Johnston Dr. Peter Johnston
Orthopedics Advisor

Dr. Peter Johnston

Orthopedics Advisor

Dr. Johnston, is an orthopedic surgeon whose passion is driven by the care and treatment of patients with shoulder and elbow conditions.

He is currently in private practice at the Centers for Advanced Orthopedics, serves as an Associate Professor of Orthopedic Surgery at Georgetown University teaching the latest techniques in shoulder and elbow surgery, and is a member of the fellowship faculty at Medstar Union Memorial Hospital mentoring future shoulder and elbow specialists. He was awarded a fellowship at the prestigious Rothman Institute at Thomas Jefferson University. Here he worked with world leaders in the field of shoulder and elbow surgery, and refined his skills in complex shoulder replacement, instability, and rotator cuff repair. After completing his fellowship, he furthered his knowledge of shoulder replacement in France working with master surgeons specifically focused on reverse shoulder replacement.

He is an active society member in the American Shoulder Elbow Surgeons, has numerous publications in peer-reviewed journals and textbooks, and has presented at national and international conferences. He is involved in multiple collaborative research efforts to further the understanding of the natural history of shoulder replacement and functional outcomes that allow a return to sport. He has served abroad as a primary investigator in an Investigational Device Exemption study - to evaluate the efficacy and safety of a new bearing surface for partial shoulder replacement for young active patients with severe arthritis. Dr. Johnston carries multiple patents.

LEADERSHIP
Jeff Jochims Jeff Jochims
CEO

Jeff Jochims

Chief Executive Officer

25+ years of leadership in the life sciences and healthcare industries, including long executive tenures at industry leaders Thermo Fisher Scienfic and Owens & Minor. Mr. Jochims has deep experience in entrepreneurial start-ups as well as global life sciences and healthcare companies of all sizes. Businesses under Jochims’ influence have consistently delivered customer-centric operational excellence and market share gains.

C-suite Officer at NYSE:OMI (COO) & 15 years as an executive leader at NYSE:TMO (Global President, Fisher Scientific). Educ: JD (U of Pittsburgh) & BA (U of Illinois).

email Jeff Jochims    
Ilker Bayer Dr. Ilker Bayer
Chief Scientist

Dr. Ilker Bayer

Chief Scientist

Dr. Bayer completed his doctoral studies in chemical engineering at the University of Illinois, where his research concentrated on the interactions between surfaces and liquids, as well as interface science. He was a visiting and post-doctoral researcher in the Mechanical and Aerospace Engineering Departments at both the University of Illinois and the University of Virginia. Subsequently, Dr. Bayer served as a research scientist at the Italian Institute of Technology (iit) for fifteen years. He holds the position of visiting professor at the University of Virginia.

Dr. Bayer's research endeavors primarily revolve around functional coatings, hybrid nanomaterials, controlled drug release, and the development of bio-based polymer composites for applications in biomedical engineering. According to Google Scholar his h-index is 62 and Dr. Bayer has been involved in the filing and granting of thirty patents, demonstrating his innovative approach and commitment to advancing scientific knowledge and technological advancements

Eugene Duan Dr. Eugene Duan
Analytical Chemist

Dr. Eugene Duan

Analytical Chemist

Dr. Duan's focus is on iodine technological research and product developments in the fields of dermatology, medical devices, medicine, and agricultural as well as aquacultural disinfectants. Before joining I2Pure, Dr. Duan served as a consultant for several companies in product research and marketing.

Dr. Duan founded and was a co-partner in three companies in China with a focus in the fields of agriculture and aquaculture, medical devices, and pharmaceuticals. He held various positions including legal representative, chair of board, president, vice president or chief technology officer, with these firms. He was with Symbollon Pharmaceuticals as a senior scientist and later as director of the research and development department from 1994 to 2002. He has authored over a dozen publications and patents and obtained various degrees and awards.

ADVISORS
Jack Kessler Dr. Jack Kessler
Chief Scientific Officer

Dr. Jack Kessler

Chief Scientific Officer

World-renowned scientist on molecular iodine technology. Past senior scientist at Hoffman-LaRoche & senior principal systems engineer at Elbit Systems of America. He was senior scientist in new technology evaluation at Hoffman-LaRoche, before becoming senior principal systems engineer at Elbit Systems of America. Kessler is a member of the founding team of Symbollon Pharmaceuticals, Iotech International, and I2Pure, where he is Chief Science Officer.

Victor Nizet Dr. Victor Nizet
Chief Medical Officer

Dr. Victor Nizet

Chief Medical Officer

Dr. Nizet is a professor of Pediatrics, Vice Chair for Basic Research, and Chief of the Division of Host-Microbe Systems & Therapeutics at the University of California, San Diego (UCSD) School of Medicine. He is also a professor at UCSD Skaggs School of Pharmacy & Pharmaceutical Sciences. He has authored over 520 peer-reviewed publications and has collaborated with biotechnology professionals in developing new antibiotic and immune-based therapies or vaccines.

At UC San Diego, he leads a large basic and translational research laboratory studying bacterial pathogenesis, innate immunity, and novel approaches to the treatment of antibiotic-resistant pathogens and sepsis.

Dr. Peter Johnston Dr. Peter Johnston
Orthopedics Advisor

Dr. Peter Johnston

Orthopedics Advisor

Dr. Johnston, is an orthopedic surgeon whose passion is driven by the care and treatment of patients with shoulder and elbow conditions.

He is currently in private practice at the Centers for Advanced Orthopedics, serves as an Associate Professor of Orthopedic Surgery at Georgetown University teaching the latest techniques in shoulder and elbow surgery, and is a member of the fellowship faculty at Medstar Union Memorial Hospital mentoring future shoulder and elbow specialists. He was awarded a fellowship at the prestigious Rothman Institute at Thomas Jefferson University. Here he worked with world leaders in the field of shoulder and elbow surgery, and refined his skills in complex shoulder replacement, instability, and rotator cuff repair. After completing his fellowship, he furthered his knowledge of shoulder replacement in France working with master surgeons specifically focused on reverse shoulder replacement.

He is an active society member in the American Shoulder Elbow Surgeons, has numerous publications in peer-reviewed journals and textbooks, and has presented at national and international conferences. He is involved in multiple collaborative research efforts to further the understanding of the natural history of shoulder replacement and functional outcomes that allow a return to sport. He has served abroad as a primary investigator in an Investigational Device Exemption study - to evaluate the efficacy and safety of a new bearing surface for partial shoulder replacement for young active patients with severe arthritis. Dr. Johnston carries multiple patents.

BOARD
Doug Spitz Doug Spitz
Executive Chair of the Board

Doug Spitz

Executive Chair of the Board

For over 25 years, Mr. Spitz has specialized in delivering solutions that feature emerging and innovative technologies.

He is a past board member of the World Iodine Association in Brussels. Prior to I2Pure, he was the President of PerformanceNet Management Group. PerformanceNet delivered a broad spectrum of emerging, innovative technologies to the U.S. federal government.

Mr. Spitz served in the U.S. Army for eight years in both active and reserve officer posts in the Chemical Corps.

Joe Steinberg Joe Steinberg

Joe Steinberg

Currently the Chair of Jefferies Financial Group, Mr. Steinberg has been a Director and President here since 1979.

He has led and served on the board of eleven different companies. From 1979 to 2013, Mr. Steinberg served as President of Leucadia National Corporation. He is Chairman of the Board of Directors at St. Ann’s Center for Arts and Education located in New York’s Brooklyn DUMBO (Down Under the Manhattan Bridge Overpass) district, a Trustee of New York University, and serves on the boards of several nonprofit organizations.

Jeff Jochims Jeff Jochims
CEO

Jeff Jochims

Chief Executive Officer

25+ years of leadership in the life sciences and healthcare industries, including long executive tenures at industry leaders Thermo Fisher Scienfic and Owens & Minor. Mr. Jochims has deep experience in entrepreneurial start-ups as well as global life sciences and healthcare companies of all sizes. Businesses under Jochims’ influence have consistently delivered customer-centric operational excellence and market share gains.

C-suite Officer at NYSE:OMI (COO) & 15 years as an executive leader at NYSE:TMO (Global President, Fisher Scientific).

email Jeff Jochims    
Jack Kessler Dr. Jack Kessler
Chief Scientific Officer

Dr. Jack Kessler

Chief Scientific Officer

World-renowned scientist on molecular iodine technology. Past senior scientist at Hoffman-LaRoche & senior principal systems engineer at Elbit Systems of America. He was senior scientist in new technology evaluation at Hoffman-LaRoche, before becoming senior principal systems engineer at Elbit Systems of America. Kessler is a member of the founding team of Symbollon Pharmaceuticals, Iotech International, and I2Pure, where he is Chief Science Officer.

Lee Larson Lee Larson

Lee Larson

Lee has been a leader in the investment industry for 16 years and held prior positions such as Fund Manager under Fundamental Global and Senior Vice President with Capital Wealth Advisors. Lee serves on the boards of 27 Software U.S. Inc. d/b/a DXterity Solutions, True Health Solutions Inc., and Beacon Health Benefits Inc.

BOARD
Doug Spitz Doug Spitz
Executive Chair of the Board

Doug Spitz

Executive Chair of the Board

For over 25 years, Mr. Spitz has specialized in delivering solutions that feature emerging and innovative technologies.

He is a past board member of the World Iodine Association in Brussels. Prior to I2Pure, he was the President of PerformanceNet Management Group. PerformanceNet delivered a broad spectrum of emerging, innovative technologies to the U.S. federal government.

Mr. Spitz served in the U.S. Army for eight years in both active and reserve officer posts in the Chemical Corps.

Joe Steinberg Joe Steinberg

Joe Steinberg

Currently the Chair of Jefferies Financial Group, Mr. Steinberg has been a Director and President here since 1979.

He has led and served on the board of eleven different companies. From 1979 to 2013, Mr. Steinberg served as President of Leucadia National Corporation. He is Chairman of the Board of Directors at St. Ann’s Center for Arts and Education located in New York’s Brooklyn DUMBO (Down Under the Manhattan Bridge Overpass) district, a Trustee of New York University, and serves on the boards of several nonprofit organizations.

Jeff Jochims Jeff Jochims
CEO

Jeff Jochims

Chief Executive Officer

25+ years of leadership in the life sciences and healthcare industries, including long executive tenures at industry leaders Thermo Fisher Scienfic and Owens & Minor. Mr. Jochims has deep experience in entrepreneurial start-ups as well as global life sciences and healthcare companies of all sizes. Businesses under Jochims’ influence have consistently delivered customer-centric operational excellence and market share gains.

C-suite Officer at NYSE:OMI (COO) & 15 years as an executive leader at NYSE:TMO (Global President, Fisher Scientific).

email Jeff Jochims    
Jack Kessler Dr. Jack Kessler
Chief Science Officer

Dr. Jack Kessler

Chief Science Officer

World-renowned scientist on molecular iodine technology. Past senior scientist at Hoffman-LaRoche & senior principal systems engineer at Elbit Systems of America. He was senior scientist in new technology evaluation at Hoffman-LaRoche, before becoming senior principal systems engineer at Elbit Systems of America. Kessler is a member of the founding team of Symbollon Pharmaceuticals, Iotech International, and I2Pure, where he is Chief Science Officer.

Lee Larson Lee Larson

Lee Larson

Lee has been a leader in the investment industry for 16 years and held prior positions such as Fund Manager under Fundamental Global and Senior Vice President with Capital Wealth Advisors. Lee serves on the boards of 27 Software U.S. Inc. d/b/a DXterity Solutions, True Health Solutions Inc., and Beacon Health Benefits Inc.